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VIEW AND REVIEW
Far beyond the motor neuron: the role of glial 
cells in amyotrophic lateral sclerosis
Muito além do neurônio motor: o papel das células da glia na esclerose lateral amiotrófica
Paulo Victor Sgobbi de Souza1, Wladimir Bocca Vieira de Rezende Pinto1, Flávio Moura Rezende Filho1, 
Acary Souza Bulle Oliveira1 
Motor neuron disease represents an important group 
of adult-onset progressive neurodegenerative motor con-
ditions, typified primarily by upper and lower motor neu-
ron compromise in amyotrophic lateral sclerosis (ALS)1,2. 
Amyotrophic lateral sclerosis results from progressive neu-
rodegenerative processes of the central nervous system 
(CNS) involving the motor cortex, brainstem motor nuclei 
and anterior horn of spinal cord3. Specific clinical, electro-
physiological and neuroimaging findings guarantee a defini-
tive diagnosis by using the revised El Escorial diagnostic 
criteria for ALS1. Although alpha motor neuron and corti-
cal upper motor neuron diseases establish the motor clini-
cal commitment, its pathophysiological mechanisms are 
wider and involve a complex network of cell interactions, 
non-neuronal cell roles and molecular mechanisms involv-
ing dysfunction of glial cells. Despite great improvement 
in its proper clinical, neurophysiological and radiological 
diagnosis, pharmacologic management is still based on 
symptom exclusion therapy measures4. 
Different mechanisms have been postulated as dys-
functions in ALS including motor neuron oxidative stress 
(including endoplasmatic reticulum stress), glutamate 
direct excitotoxicity, dysfunction in electrolytes and vesic-
ular homeostasis, disruption of axonal transport (of pro-
teins and mitochondria along microtubules), exosome and 
vesicular trafficking (including dysregulated endosomal 
trafficking), motor neuron apoptosis (including mito-
chondria-mediated mechanisms), dysfunction in the ubiq-
uitin-proteasome system and in autophagy, mitochondrial 
dysfunction, aberrant RNA metabolism and processing, 
and glial cell pathology5,6,7,8. There is also growing evidence 
that other underlying hypothetical mechanisms affecting, 
primarily, the glial cells should include emergent latent 
virus infection and misfolded infectious protein (prion-like 
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ABSTRACT
Motor neuron disease is one of the major groups of neurodegenerative diseases, mainly represented by amyotrophic lateral sclerosis. 
Despite wide genetic and biochemical data regarding its pathophysiological mechanisms, motor neuron disease develops under a complex 
network of mechanisms not restricted to the unique functions of the alpha motor neurons but which actually involve diverse functions of 
glial cell interaction. This review aims to expose some of the leading roles of glial cells in the physiological mechanisms of neuron-glial cell 
interactions and the mechanisms related to motor neuron survival linked to glial cell functions.
Keywords: motor neurons; astrocyte; microglia; amyotrophic lateral sclerosis; motor neuron disease. 
RESUMO
A doença do neurônio motor constitui um dos principais grupos de doenças neurodegenerativas, representadas principalmente pela 
esclerose lateral amiotrófica. Apesar dos amplos dados genéticos e bioquímicos em relação aos seus mecanismos fisiopatológicos, 
a doença do neurônio motor se desenvolve sob uma complexa rede de mecanismos não restritos às funções particulares dos neurônios 
motores alfa, mas, na verdade, envolvendo diversas funções interativas das células da glia. Esta revisão tem como objetivo expor alguns 
dos principais papéis das células da glia nos mecanismos fisiológicos de interações neurônio-glia e os mecanismos relacionados à 
sobrevivência do neurônio motor ligados a funções das células da glia.
Palavras-chave: neurônios motores; astrócitos; microglia; esclerose lateral amiotrófica; doença do neurônio motor.
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effect)7. This review aims to summarize the most impor-
tant data established on the role of glial cell types in ALS.
PRIMARY GLIAL CELL TYPES AND FUNCTIONS 
RELATED TO MOTOR NEURODEGENERATION 
Most information about physiopathological mecha-
nisms involved in ALS has been through post-mortem his-
topathological evaluation and from mouse models related 
to different induced mutations, mainly the human trans-
genic mouse model with G93A mutation in the gene SOD1 
(Cu-Zn superoxide dismutase-1), involved in an autosomal 
inherited form of ALS, with overexpression of SOD1 pro-
tein. In motor neuron disease linked to TAR DNA-binding 
protein 43 (TDP43), fused in sarcoma protein (FUS), ALS2 
gene, VAPB gene, OPTN gene and C9ORF72 gene (chromo-
some 9 open reading frame 72) mechanisms7,9, few data 
regarding the involvement of glial cells are available, com-
pared with cases related to SOD1 gene mutations. 
There is no doubt about the importance of cellular and 
non-neuronal extracellular microenvironments in the regu-
lation of mechanisms involved in neuron survival10 and in 
early stage activation of astroglial and microglial cells in 
ALS pathogenesis11. Changes in the adequate formation and 
balance of the neuron-glia network and abnormal assembly 
of its components represent one of the main mechanisms 
related to different, slowly progressive, focal and global neu-
ropsychiatric dysfunctions, such as ALS10. 
Although nearly all glial cells are involved in ALS patho-
genesis, astrocytes and microglia have major roles12 (Figure 1). 
Protoplasmic and fibrous astrocytes, microglial cells and oli-
godendrocytes represent the major types of glial cells in the 
CNS and most non-neuronal pathological processes related 
to neurodegeneration involve these cell types. The role of 
ependymal cells and choroid plexus epithelial cells are not 
yet understood, specifically in ALS pathogenesis, and have 
not been adequately studied10. Mechanisms involving other 
glial cell types including Schwann cells, oligodendrocytes 
and NG2 (nerve-glia factor 2 proteglycan antibody) positive 
cells are also not well established12. 
Neuropathological studies have shown that reactive 
astrocytes, microglia activation, and macrophage and 
T-lymphocyte infiltration of neural tissues overcoming 
classical motor neuron dysfunction in ALS3 (Figure 2). 
There is a fine immune cross-talk in ALS pathogenesis in 
a suggestive immunopattern shown by reactive microg-
lia (with a mixture of minor expression of CX3CL1 and its 
receptor and CD200 and its receptor and major expression 
of IL-6, IL-12, TNF-α and reactive oxygen species); acti-
vated macrophages (with higher expression levels of IL-1β, 
COX2 and glycoprotein CD68), reactive astrocytes (raised 
SDF-1α); and reactive T-lymphocytes (starting with a 
preponderance of regulatory T lymphocytes, and, during 
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Figure 1. The ALS molecular profile. Glial cells interact with neurons in many different ways to maintain neural tissue health, 
for which a peculiar cytoarchitecture is required, as shown. Molecular mechanisms and molecules recently implicated in the 
pathophysiology of motor neuron disease are listed, according to cell types. 
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progression, with a predominance of homolog effector T 
lymphocytes with reduction of their neuroprotector effect 
with raised reactive oxygen species, inducible nitric oxide 
synthase and NOX2/phagocyte oxidase gp91phox)3,13.
Environmental factors and extraneuronal disturbances are 
also essential in its immunopathogenesis. For example, it has 
also been proven that the direct modulatory effect of vitamin 
D in glial cell function in patients with ALS affects different cell 
and extracellular matrix mechanisms: cell-signaling mecha-
nisms (glutamate, matrix metalloproteinases, mitogen-acti-
vated protein kinase pathways, Wnt/β-catenin signaling path-
way, prostaglandins and reactive oxygen species release, and 
nitric oxide synthase), major histocompatibility complex class 
II molecules, toll-like receptors, poly (ADP-ribose) polymerase-1, 
heme oxygenase-1, calcium-binding proteins, and a reduced 
form of nicotinamide adenine dinucleotide phosphate14.
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Figure 2. Glial cells functioning in healthy subjects and in ALS patients. a1. Astrocyte: nourishes motor neurons through the 
synthesis of amino acids, neurotransmitters and neurotrophic molecules; clears extracellular glutamate via specific transporters 
(EAAT2); offers antioxidant defenses. a2. Reactive astrocyte: reduced production of neurotrophic factors; inefficient glutamate 
clearance; induces metabolic pathways that favor oxidative stress. b. Motor neuron. c1. Microglia: expresses ligands and receptors 
with neuroprotective roles (CX3CL1/ CX3CL1R, CD200/CD200R); minimal production of oxygen and nitrogen reactive species. 
c2. Reactive microglia: increased synthesis and release of oxidant agents (H2O2, NO2) and cytokines (IL-6, IL-12, IL-23, TNF-α). 
d1. Monocyte: no chemotactic stimulus. d2. Macrophage: invades neural tissue, secretes molecules that perpetuate inflammation 
and neuron loss (IL-1 beta), increased expression of COX-2. e1. T-lymphocyte: neuroprotective production of IGF-1, brain-derived 
neurotrophic factor and glial-derived neutrotrophic factor. e2. Reactive T-lymphocyte: secretes IL-4, IL-10, TGF-β; increased 
expression of INOS and NOX-2. f. Skeletal muscle fiber. 
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At different stages of evolution, there are remarkable 
changes in neuroinflammation patterns and cell activation 
in ALS. Briefly, there is no doubt that the balance of astro-
cyte neuroprotective or microglia pro-inflammatory func-
tions generate a progression, or decrease, in the rate of pri-
mary intrinsic motor neuron degeneration15,16. During the 
late stages of ALS, there is a wide increase in cytotoxic T cell 
infiltration of the spinal cord leading to a pro-neurotoxic pro-
file of cytokines and chemokines and decreases in local lev-
els of neuroprotective neurotrophic factors, such as GLT1 
(SLC1A2) and GLAST (SLC1A3)16. Next, we will sumarize 
the most relevant physiopathological functions described in 
each glial cell type. 
ASTROCYTE ROLE IN ALS PATHOGENESIS
Although classically related to neuronal regulation func-
tions, astrocytes are involved in regulation of the extracel-
lular microenvironment in neurotransmitters at synapses 
and during their developmental stages; control of signal-
ing of CNS vascular development (including modulation of 
blood-brain-barrier development); neurotrophic support and 
stimulation for diverse neurons, maintenance of intercellular 
signaling (including modulation of excitatory synaptic trans-
mission via release and propagation of glutamatergic stim-
uli); and neurometabolites and ionic regulation and homeo-
stasis (acid and fluid equilibrium)3,8,13,17,18,19.   
The main mechanism involving astrocytes in ALS 
pathophysiology is dysfunction of glutamate transporters20 
with loss of the astroglial glutamate transporter EAAT2 
(by aberrant RNA splicing, exon skipping and intron reten-
tion) in the motor cortex and in the anterior horn of the 
spinal cord, disclosing its important function in excitotoxic 
damage in sporadic ALS. As previously mentioned, astro-
cytes participate in glutamate clearance from the synaptic 
clefts providing more balanced levels of extracellular excit-
atory neurotransmission, the defective reuptake of which 
being the key mechanism in mouse models linked to EAAT2 
transporter dysfunctions. It has also been proved in mutant 
SOD1 mice that astrocytes directly regulate the expression 
of glutamate receptor subunit GluR2 in AMPA receptors 
of motor neurons12. Other proven mechanisms included 
impaired release of multiple neurotrophic factors, includ-
ing glial-derived neutrotrophic factor, ciliary neurotrophic 
factor, vascular endothelial growth factor and brain-derived 
neurotrophic factor12. Astrocytes with SOD1 gene muta-
tion produce reactive oxygen species and soluble mole-
cules with a selective toxicity pattern to spinal cord motor 
neurons. Another proven mechanism in the SOD1 mouse 
model includes activation of the pro-nerve growth factor 
(NGF)-p75 receptor-signaling pathway involved in direct 
astrocyte toxicity to motor neurons8.
It has also been established that high levels of cyclo-
oxygenase 2 is involved in prostaglandin E2 synthesis and 
hyperstimulation of NMDA glutamate receptor activation 
of COX2 and subsequent production of reactive oxygen spe-
cies and prostaglandin E2, and this enhances glutamate 
release from astrocytes20. 
THE ROLE OF MICROGLIA IN ALS PATHOGENESIS
Microglia represent the major primary resident phago-
cytic immune cells of the CNS associated with some 
astrocyte immune functions, secreting pro-inflammatory 
immune response molecules including cytokines and 
chemokines and anti-inflammatory molecules during 
resolution of neural damage, and stimulating the release 
of neurotrophic growth factors. Microglia result from dif-
ferentiation of precursors of the monocyte/mesodermal 
lineage of hematopoietic stem cells that normally protect 
against microbial infection, abnormal aggregated protein, 
immunoglobulin-antigen complexes and microhemor-
rhagic content3,21. 
Microglial activation is a common hallmark of many 
neurodegenerative diseases, including ALS, despite the 
fact that it results mainly from proliferation of myeloid pre-
cursor cells22. Activated microglia releases proinflamma-
tory cytokines (tumor necrosis factor-α, interleukin-1β, 
interleukin-12, interferon-γ), mitogenic factors (monocyte 
chemoattractant protein 1, macrophage colony stimulating 
factor), neurotrophic factors (insulin-like growth factor-1), 
and anti-inflammatory cytokines (tumor growth factor-β)12. 
There is a direct neuropathological correlation of microg-
lial activation with severity of upper motor neuron damage. 
Diminishing the toxicity of mutant SOD1 transgene within 
microglia of mice has been shown to significantly slow dis-
ease progression of ALS23. It has also been shown that the 
CCAAT/enhancer binding protein-β is enhanced in acti-
vated microglial cells of the spinal cord of ALS mouse mod-
els with SOD1 gene mutation, promoting higher expression of 
nitric oxide synthase-2, cyclooxygenase-2 and upregulation 
of other proinflammatory gene expression24. 
Reactive oxygen species and cytokines increase motor 
neuron susceptibility to glutamate excitotoxicity and inhibit 
expression of astrocytic glutamate transporters diminishing 
glutamate uptake and perpetuating this neurotransmitter’s 
neurotoxicity mechanism25.
Nuclear factor-kappa B (NF-кB) is upregulated in the spi-
nal cord of mouse models and patients with ALS, although 
inhibitory effects of its pathway in astrocytes did not prevent 
neurodegeneration or rescue motor neuron death induced by 
microglia. However, the modulatory effect in NF-кB pathway 
impairs proinflammatory activation of microglia26.
Neuropathological studies have also established the acti-
vation of microglia and T-cell infiltration in different stages 
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of ALS evolution25. It is widely known that the peripheral 
immune system represents a crucial stage in the main patho-
physiological mechanism: T-lymphocytes directly cross the 
bood-brain barrier, and interact with resident primary microg-
lia triggering two different immunophenotypes depending on 
the clinical and pathological stage of the ALS: an M2 protective 
anti-inflammatory profile in early processes involving regula-
tory T-cells and IGF-1, or, an M1 cytotoxic profile in late pro-
cesses induced by fractalkine (CX3CL1) and CD200 involving 
Th1 cells and interleukin, and other substances such as IL-1β, 
IL-6, IL-12, IL-23, reactive oxygen species (mainly H2O2) and 
TNF-α15,27. Microglia production of IL-10, induced by cytokines 
from leptomeningeal cells, has also been shown. 
OTHER GLIAL CELLS INVOLVED IN ALS PATHOGENESIS
NG2 cells, synantocytes or pericytes, participate in CNS 
immune mechanisms of defense, producing new astro-
cytes, oligodendrocytes and neurons, in some situations 
and specific areas of the CNS. NG2 cells become astrocytes 
by proinflammatory cytokine signaling in most ALS stages12. 
Oligodendrocytes also regulate local neuronal microenvi-
ronments. They represent the main myelinating cells of the 
CNS28. Oligodendrocytes are involved in mechanisms of cen-
tral myelination and provide metabolic sustenance to motor 
neurons. Amyotrophic lateral sclerosis does not represent a 
primary oligodendrocyte disease.
The effective role of NG2+ cells in the astrogliosis pro-
cess in ALS is still uncertain. NG2+ cells produce new 
oligodendrocytes, neurons and perhaps astrocytes after 
an injury, changing the cellular microenvironment. In ALS, 
cell proliferation rates are enhanced in regions of motor 
neuron degeneration, but myelination and remyelination 
defects are also found3. Few studies have explored the role 
of myelinated oligodendrocytes in ALS pathogenesis, which 
influence motor neurons through neurotrophic factors 
release and regeneration after neuronal injury. It has also 
been shown how oligodendrocytes and their NG2+ progeni-
tors mediate neuron loss in ALS, the abnormal rate of pro-
liferation in mouse models secondary to oligodendrocyte 
degeneration, and to the progressive neuroinflammatory 
and neurodegenerative processes. The role of Schwann cells 
in ALS pathogenesis remains undefined12. 
FINAL REMARKS
Motor neuron disease represents an important group 
of neurodegenerative disorders, mainly represented by ALS. 
Primary alpha motor neuron involvement and degeneration 
and secondary mechanisms including glial cell pathological 
processes represent the most important features in the patho-
physiology of ALS. Astrocyte and microglial dysfunctions have 
been widely demonstrated in patients and animal models of 
ALS. More studies are needed to establish specific molecular 
features linked to glial dysfunction at the microcellular level 
and its extracellular involvement, to allow new pharmacologi-
cal perspectives and provide data about the natural history of 
the different genetic forms and variants of ALS. 
References
1. Oliveira AS, Pereira RD. Amyotrophic lateral sclerosis 
(ALS): three letters that change the people’s life. 
For ever. Arq Neuropsiquiatr. 2009;67(3A):750-82. 
doi:10.1590/S0004-282X2009000400040
2. Radunović A, Mitsumoto H, Leigh PN. Clinical care of patients with 
amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(10):913-25. 
doi:10.1016/S1474-4422(07)70244-2
3. Rizzo F, Riboldi G, Salani S, Nizzardo M, Simone C, Corti S et al. 
Cellular therapy to target neuroinflammation in amyotrophic 
lateral sclerosis. Cell Mol Life Sci. 2014;71(6):999-1015. 
doi:10.1007/s00018-013-1480-4
4. Andrews J. Amyotrophic lateral sclerosis: clinical management 
and research update. Curr Neurol Neurosci Rep. 2009;9(1):59-68. 
doi:10.1007/s11910-009-0010-0
5. Shi P, Wei Y, Zhang J, Gal J, Zhu H. Mitochondrial dysfunction 
is a converging point of multiple pathological pathways in 
amyotrophic lateral sclerosis. J Alzheimers Dis. 2010;20:S311-24. 
doi:10.3233/JAD-2010-100366
6. Brites D, Vaz AR. Microglia centered pathogenesis in ALS: 
insights in cell interconnectivity. Front Cell Neurosci. 2014;8:117. 
doi:10.3389/fncel.2014.00117 
7. Sica RE, Nicola AF, Deniselle MC, Rodriguez G, Monachelli GM, Peralta LM 
et al. Sporadic amyotrophic lateral sclerosis: new hypothesis regarding 
its etiology and pathogenesis suggests that astrocytes might be the 
primary target hosting a still unknown external agent. Arq Neuropsiquiatr. 
2011;69(4):699-706. doi:10.1590/S0004-282X2011000500023
8. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular 
pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat 
Rev Neurol. 2011;7(11):616-30. doi:10.1038/nrneurol.2011.152
9. Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in 
amyotrophic lateral sclerosis and frontotemporal dementia. Lancet 
Neurol. 2010;9(10):995-1007. doi:10.1016/S1474-4422(10)70195-2
10. Araque A. Astrocyte-neuron signaling in the brain: implications for 
disease. Curr Opin Investig Drugs. 2006;7(7):619-24. 
11. Neusch C, Bähr M, Schneider-Gold C. Glia cells in amyotrophic lateral 
sclerosis: new clues to understanding an old disease? Muscle Nerve. 
2007;35(6):712-24. doi:10.1002/mus.20768
12. Lasiene J, Yamanaka K. Glial cells in amyotrophic lateral sclerosis. 
Neurol Res Int. 2011;2011:718987. doi:10.1155/2011/718987
13. Blackburn D, Sargsyan S, Monk PN, Shaw PJ. Astrocyte function 
and role in motor neuron disease: a future therapeutic target? Glia. 
2009;57(12):1251-64. doi:10.1002/glia.20848
14. Long K, Nguyễn LT. Roles of vitamin D in amyotrophic lateral 
sclerosis: possible genetic and cellular signaling mechanisms. 
Mol Brain. 2013;6(1):16. doi:10.1186/1756-6606-6-16
15. Evans MC, Couch Y, Sibson N, Turner MR. Inflammation and 
neurovascular changes in amyotrophic lateral sclerosis. Mol Cell 
Neurosci. 2013;53:34-41. doi:10.1016/j.mcn.2012.10.008
854 Arq Neuropsiquiatr 2016;74(10):849-854
16. Philips T, Robberecht W. Neuroinflammation in 
amyotrophic lateral sclerosis: role of glial activation in 
motor neuron disease. Lancet Neurol. 2011;10(3):253-63. 
doi:10.1016/S1474-4422(11)70015-1
17. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology”. Acta 
Neuropathol. 2010;119(1):7-35. doi:10.1007/s00401-009-0619-8
18. Boillée S, Vande Velde C, Cleveland DW. ALS: a disease of motor 
neurons and their nonneuronal neighbors. Neuron. 2006;52(1):39-59. 
doi:10.1016/j.neuron.2006.09.018
19. Maragakis NJ, Rothstein JD. Mechanisms of Disease: 
astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 
2006;2(12):679-89. doi:10.1038/ncpneuro0355
20. Seifert G, Schilling K, Steinhäuser C. Astrocyte dysfunction in 
neurological disorders: a molecular perspective. Nat Rev Neurosci. 
2006;7(3):194-206. doi:10.1038/nrn1870
21. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta 
Neuropathol. 2010;119(1):89-105. doi:10.1007/s00401-009-0622-0
22. Gowing G, Philips T, Van Wijmeersch B, Audet JN, Dewil M, Van Den 
Bosch L et al. Ablation of proliferating microglia does not affect 
motor neuron degeneration in amyotrophic lateral sclerosis caused 
by mutant superoxide dismutase. J Neurosci. 2008;28(41):10234-44. 
doi:10.1523/JNEUROSCI.3494-08.2008
23. Yamanaka K, Yamashita H. [ALS and microglia: a player 
for non-cell-autonomous neuron death]. Brain Nerve. 
2007;59(10):1163-70. Japanese.
24. Valente T, Mancera P, Tusell JM, Serratosa J, Saura J. C/EBPβ expression 
in activated microglia in amyotrophic lateral sclerosis. Neurobiol Aging. 
2012;33(9):2186-99. doi:10.1016/j.neurobiolaging.2011.09.019
25. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: 
the good, the bad, and the resting. J Neuroimmune Pharmacol. 
2009;4(4):389-98. doi:10.1007/s11481-009-9171-5
26. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, Schmelzer L, Braun 
L, Miranda CJ et al. Microglia induce motor neuron death via the 
classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron. 
2014;81(5):1009-23. doi:10.1016/j.neuron.2014.01.013
27. Zhao W, Beers DR, Appel SH. Immune-mediated mechanisms in the 
pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune 
Pharmacol. 2013;8(4):888-99. doi:10.1007/s11481-013-9489-x
28. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta 
Neuropathol. 2010;119(1):37-53. doi:10.1007/s00401-009-0601-5
